
    
      GC1102 is a new recombinant hepatitis B human immunoglobulin. This study is composed with 2
      Parts, Part A for SAD and Part B for MAD and total 4 dosing program which is escalated after
      confirming safety. Maximum 48 subjects will be participated in the study.
    
  